Agreement signedPublished 30 Mar 2026

Lunai Bioworks Inc. /
Clemann Group, SAS

Lunai Bioworks agrees to buy Alzheimer's drug assets

Buy side: Lunai Bioworks Inc.
Buy sideLunai Bioworks Inc.
Target: Clemann Group, SAS
TargetClemann Group, SAS
Lunai Bioworks Inc. · 30 Mar 2026Source
Buy side: Lunai Bioworks Inc.
Buy sideLunai Bioworks Inc.
Target: Clemann Group, SAS
TargetClemann Group, SAS
01 / BuyerLunai Bioworks Inc.
02 / TargetClemann Group, SAS
Source for the buyer and target: Lunai Bioworks Inc.

For the buyer and target.

“Sacramento, CA — March 26, 2026 — Lunai Bioworks, Inc. (NASDAQ: LNAI) today announced it has executed a binding $20 million strategic transaction to acquire blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer’s drug assets from the Clemann Group, SAS or its assignee.”

Published 30 Mar 2026

Open the source
01

What happened

Lunai Bioworks signed a binding agreement with Clemann Group, SAS to acquire blood-brain barrier delivery technology and related central nervous system Alzheimer's drug assets. The deal is structured as a $20.0 million strategic investment paid in Series B Convertible Preferred Stock. [01]

The closing remains subject to customary conditions, so the transaction is not yet complete. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Lunai Bioworks Inc.

Lunai Bioworks agrees to buy Alzheimer's drug assets

This document is the source for the companies, stage, figure and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by Lunai Bioworks Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.